Proteins inform survival-based differences in patients with glioblastoma.

ABSTRACT:

Background

Improving the care of patients with glioblastoma (GB) requires accurate and reliable predictors of patient prognosis. Unfortunately, while protein markers are an effective readout of cellular function, proteomics has been underutilized in GB prognostic marker discovery.

Methods

For this study, GB patients were prospectively recruited and proteomics discovery using liquid chromatography-mass spectrometry analysis (LC-MS/MS) was performed for 27 patients including 13 short-term survivors (STS) (≤10 months) and 14 long-term survivors (LTS) (≥18 months).

Results

Proteomics discovery identified 11 941 peptides in 2495 unique proteins, with 469 proteins exhibiting significant dysregulation when comparing STS to LTS. We verified the differential abundance of 67 ou

SUBMITTER: Stetson LC 

PROVIDER: S-EPMC7212893 | biostudies-literature | 2020 Jan-Dec

REPOSITORIES: biostudies-literature